What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc., nothing.
The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.
Study outcome won't sway company on eye drug
Senator John McCain said Friday he’ll vote against the GOP-only Obamacare repeal proposal, becoming the second...
Aaron Hernandez, the former New England Patriots tight end who committed suicide in April while serving...
State and local groups now know how much funding they'll have to help enroll people in...
